In this randomized trial, insulin sensitizers or sitagliptin facilitated SIIT implementation by reducing insulin requirements and accelerating near‐normoglycemia achievement in adults with newly diagnosed type 2 diabetes mellitus and marked hyperglycemia. The gene discussed is INS; the disease is type 2 diabetes mellitus.